ArticleOncoTargets and therapy2018
Radiofrequency ablation of hepatocellular carcinoma: a meta-analysis of overall survival and recurrence-free survival.
Article in OncoTargets and therapy, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 2 syntheses or guidelines pooled it, 46 citations in OpenAlex.
- SEOM-GEMCAD-TTD clinical guidelines for the management of hepatocarcinoma patients (2023).Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2024Guideline
- Meta-analysis of Percutaneous vs. Surgical Approaches Radiofrequency Ablation in Hepatocellular Carcinoma.Frontiers in surgery · 2021Pooled it
- Efficacy and Safety of Microwave Ablation in Patients With Hepatocellular Carcinoma With Decompensated Liver Cirrhosis: A Retrospective Study.Canadian journal of gastroenterology & hepatology · 2025Article
- The Clinical Association Between the Inflammation-Nutritional Condition and Prognosis of Locally Advanced Intrahepatic Cholangiocarcinoma After R0 Resection: Evidence from Competing Risk and Propensity Matching Analysis.Journal of inflammation research · 2024Article
- Autophagy-amplifying nanoparticles evoke immunogenic cell death combined with anti-PD-1/PD-L1 for residual tumors immunotherapy after RFA.Journal of nanobiotechnology · 2023Article
- Brazilian Landscape of Hepatocellular Carcinoma.JCO global oncology · 2023Review
- Evaluating treatment response following locoregional therapy for hepatocellular carcinoma: A review of the available serological and radiological tools for assessment.JGH open : an open access journal of gastroenterology and hepatology · 2023Review
- Management of Hepatocellular Carcinoma in Decompensated Cirrhotic Patients: A Comprehensive Overview.Cancers · 2023Review
- Article
- Stereotactic Microwave Ablation of Hepatocellular Carcinoma: The Impact of Tumor Size and Minimal Ablative Margin on Therapeutic Success.Tomography (Ann Arbor, Mich.) · 2022Article
- Prognostic Role of a New Index Tested in European and Korean Advanced Biliary Tract Cancer Patients: the PECS Index.Journal of gastrointestinal cancer · 2022Article
- Radiofrequency ablation in the management of primary hepatic and biliary tumors.World journal of gastrointestinal oncology · 2022Review
- Rim-arterial enhancing primary hepatic tumors with other targetoid appearance show early recurrence after radiofrequency ablation.European radiology · 2021Article
- Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2021Review
- Locoregional therapies in the era of molecular and immune treatments for hepatocellular carcinoma.Nature reviews. Gastroenterology & hepatology · 2021Review
- Tumor Biomarkers and Interventional Oncology: Impact on Local Outcomes for Liver and Lung Malignancy.Current oncology reports · 2021Review
- Utility of neutrophil-to-lymphocyte ratio to identify long-term survivors among HCC patients treated with sorafenib.Medicine · 2020Observational
- Prognostic Role of a New Index (RAPID Index) in Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib: Training and Validation Cohort.Gastrointestinal tumors · 2019Article
- Characteristics and Prognostic Factors of Hepatitis B Virus-associated Hepatocellular Carcinoma in Patients with and without Cirrhosis.Euroasian journal of hepato-gastroenterologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: So far, no randomized trial or meta-analysis has been conducted on overall survival (OS) and recurrence-free survival (RFS) factors in patients treated with radiofrequency ablation (RFA) alone. The purpose of this meta-analysis was to evaluate prognostic factors of OS and RFS in patients treated with RFA. Methods: A primary analysis was planned to evaluate the clinical prognostic factor of OS. RFS was the secondary aim. Thirty-four studies published from 2003 to 2017 were analyzed. They included 11,216 hepatocellular carcinoma patients. Results: The results showed that Child-Pugh B vs Child-Pugh A (HR =2.32; 95% CI: 2.201-2.69; Conclusion: Our meta-analysis highlighted that the maximum benefit of RFA in terms of OS and RFS is reached in the presence of Child-Pugh A, albumin-bilirubin score 1, single-nodule tumor sized <2 cm, and alpha-fetoprotein <20 ng/mL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.